Karmen Goosey
Family · North Kansas City, MONPI 1609860022
Payments from drug & device makers
Across 429 payments — averaging $24.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$928
- Boehringer Ingelheim$671
- Pfizer$511
- Lilly USA, LLC$498
- plus $4K from 32 others
What the payments were for
- Consulting fees$5005%
- Food & beverage$9,92494%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $2,505 |
| AbbVie | 68 | $1,568 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $928 |
| Boehringer Ingelheim | 41 | $671 |
| Pfizer | 33 | $511 |
| Lilly USA, LLC | 31 | $498 |
| Amgen | 14 | $390 |
| Neurocrine Biosciences, Inc. | 8 | $331 |
| Otsuka America Pharmaceutical, Inc. | 11 | $281 |
| Teva Pharmaceuticals USA, Inc. | 3 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $263 |
| GSK | 4 | $257 |
| Vanda Pharmaceuticals Inc. | 13 | $253 |
| Merck | 17 | $243 |
| Bayer | 9 | $177 |
| Lundbeck LLC | 8 | $150 |
| Novo Nordisk | 9 | $139 |
| Axsome Therapeutics, Inc. | 7 | $132 |
| Sanofi-aventis U.S. LLC | 1 | $113 |
| Urovant Sciences Inc | 1 | $112 |
| Kowa Pharmaceuticals America, Inc. | 8 | $102 |
| Antares Pharma, Inc. | 4 | $73 |
| Neurelis, Inc. | 1 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Mylan Specialty L.p. | 1 | $71 |
| Eisai Inc. | 4 | $53 |
| Sanofi Pasteur Inc. | 1 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Exact Sciences | 2 | $31 |
| Electromed, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Medtronic | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$622
- AIRSUPRA$599
- CAPLYTA$466
- FARXIGA$351
- VRAYLAR$235
- INGREZZA$233
- Repatha$220
- FASENRA$125
- Austedo XR$122
- Mavyret$121
- QULIPTA$118
- Fanapt$117
- TRELEGY ELLIPTA$114
- SOLIQUA 100/33$113
- GEMTESA$112
How this compares
$10,506 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $128,135 |
| JardianceEmpagliflozin | 130 | $117,263 |
| MounjaroTirzepatide | 78 | $104,902 |
| FarxigaDapagliflozin Propanediol | 126 | $96,468 |
| EliquisApixaban | 74 | $67,107 |
| RexultiBrexpiprazole | 20 | $34,709 |
| XareltoRivaroxaban | 54 | $34,476 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $32,436 |
| JanuviaSitagliptin Phosphate | 34 | $27,863 |
| Spiriva RespimatTiotropium Bromide | 33 | $19,110 |
| MyrbetriqMirabegron | 23 | $18,458 |
| TrulicityDulaglutide | 17 | $16,972 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,707 |
| VascepaIcosapent Ethyl | 17 | $11,550 |
| TrintellixVortioxetine Hydrobromide | 17 | $11,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $671 | $145,488181 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,505 | $143,610223 claims |
| Novo NordiskOzempic | $139 | $128,135118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $498 | $121,87495 claims |
| PfizerEliquis | $511 | $67,10774 claims |
| MerckJanuvia, Belsomra | $243 | $36,86454 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $281 | $34,70920 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $257 | $18,82034 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $263 | $11,17717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in North Kansas City
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.